Matches in SemOpenAlex for { <https://semopenalex.org/work/W2999694147> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W2999694147 abstract "ABSTRACT Cetuximab, an epidermal growth factor receptor (EGFR)-directed antibody, is an effective treatment of patients with colorectal cancer (CRC), head and neck squamous cell cancer (HNSCC), and non-small cell lung cancer (NSCLC). However, in such a promising drug, tumor cells eventually develop the resistance to cetuximab after initial response. Recently, we uncovered the mechanism of acquired resistance to cetuximab, which is caused by ERBB2 activation through whether ERBB2 genomic amplification or ligand (heregulin) overexpression (Science Translational Medicine 2011). At first we established cetuximab-resistant clones of NSCLC and CRC cell line. Genome-wide copy number analyses revealed that ERBB2 oncogene was genetically amplified in those cetuximab-resistant clones. ERBB2 inhibition with trastuzmab or lapatinib could restore the sensitivity to cetuximab in these clones. In CRC patients treated with cetuximab (n = 233), patients with ERRB2 amplified (n = 13) had significantly shorter overall survival compared with patients with ERBB2 non-amplified. ERBB2 amplification was detected in tissue samples post-treatment in patients who acquired resistance to cetuximab. Secondary, we identified ‘heregulin’ also could lead to cetuximab resistance. Heregulin is ERBB3 ligand and preferentially induces the hetero-dimerization between ERBB2 and ERBB3. Similarly, ERBB2 was activated by heregulin. Thus we observed that heregulin could induce cetuximab resistance in vitro and in vivo. CRC patients with high expression of heregulin were significantly resistant to cetuximab, and had significantly shorter PFS and OS in cetuximab treatment. Moreover, plasma samples from patients, who acquired cetuximab resistance, had significantly higher expression of heregulin compared with pre-treatment. Our findings suggest ERBB2 activation induced both de novo and acquired resistance to cetuximab. Most importantly ERBB2 (or ERBB3) inhibitor combination therapy may conquer the cetuximab resistance. Actually clinical trials are now on-going evaluating ERBB2 or ERBB3 inhibitor combined with cetuximab. As another remaining issue, ERBB2 or heregulin could be biomarker for patient selection. West Japan Oncology Group (WJOG) is now prospectively evaluating these biomarkers in mCRC patients in clinical trial (WJOG6210G)." @default.
- W2999694147 created "2020-01-23" @default.
- W2999694147 creator A5040004004 @default.
- W2999694147 date "2012-10-01" @default.
- W2999694147 modified "2023-10-01" @default.
- W2999694147 title "Translational Study Shed the Light on ERBB2 (HER2), Playing a Key Role for Acquired Resistance to Cetuximab, Anti-EGFR Antibody" @default.
- W2999694147 doi "https://doi.org/10.1016/s0923-7534(20)31944-x" @default.
- W2999694147 hasPublicationYear "2012" @default.
- W2999694147 type Work @default.
- W2999694147 sameAs 2999694147 @default.
- W2999694147 citedByCount "0" @default.
- W2999694147 crossrefType "journal-article" @default.
- W2999694147 hasAuthorship W2999694147A5040004004 @default.
- W2999694147 hasBestOaLocation W29996941471 @default.
- W2999694147 hasConcept C115456853 @default.
- W2999694147 hasConcept C121608353 @default.
- W2999694147 hasConcept C126322002 @default.
- W2999694147 hasConcept C143998085 @default.
- W2999694147 hasConcept C170493617 @default.
- W2999694147 hasConcept C185323287 @default.
- W2999694147 hasConcept C2778560701 @default.
- W2999694147 hasConcept C2779438470 @default.
- W2999694147 hasConcept C2779998722 @default.
- W2999694147 hasConcept C2781018059 @default.
- W2999694147 hasConcept C29537977 @default.
- W2999694147 hasConcept C502942594 @default.
- W2999694147 hasConcept C526805850 @default.
- W2999694147 hasConcept C71924100 @default.
- W2999694147 hasConceptScore W2999694147C115456853 @default.
- W2999694147 hasConceptScore W2999694147C121608353 @default.
- W2999694147 hasConceptScore W2999694147C126322002 @default.
- W2999694147 hasConceptScore W2999694147C143998085 @default.
- W2999694147 hasConceptScore W2999694147C170493617 @default.
- W2999694147 hasConceptScore W2999694147C185323287 @default.
- W2999694147 hasConceptScore W2999694147C2778560701 @default.
- W2999694147 hasConceptScore W2999694147C2779438470 @default.
- W2999694147 hasConceptScore W2999694147C2779998722 @default.
- W2999694147 hasConceptScore W2999694147C2781018059 @default.
- W2999694147 hasConceptScore W2999694147C29537977 @default.
- W2999694147 hasConceptScore W2999694147C502942594 @default.
- W2999694147 hasConceptScore W2999694147C526805850 @default.
- W2999694147 hasConceptScore W2999694147C71924100 @default.
- W2999694147 hasLocation W29996941471 @default.
- W2999694147 hasOpenAccess W2999694147 @default.
- W2999694147 hasPrimaryLocation W29996941471 @default.
- W2999694147 hasRelatedWork W1966067305 @default.
- W2999694147 hasRelatedWork W1975240042 @default.
- W2999694147 hasRelatedWork W2001821686 @default.
- W2999694147 hasRelatedWork W2019443090 @default.
- W2999694147 hasRelatedWork W2062552991 @default.
- W2999694147 hasRelatedWork W2083199051 @default.
- W2999694147 hasRelatedWork W2141630197 @default.
- W2999694147 hasRelatedWork W2143902539 @default.
- W2999694147 hasRelatedWork W2327419907 @default.
- W2999694147 hasRelatedWork W2332684061 @default.
- W2999694147 hasRelatedWork W2491737197 @default.
- W2999694147 hasRelatedWork W2522163312 @default.
- W2999694147 hasRelatedWork W2560759455 @default.
- W2999694147 hasRelatedWork W2566896698 @default.
- W2999694147 hasRelatedWork W2795117080 @default.
- W2999694147 hasRelatedWork W2908755091 @default.
- W2999694147 hasRelatedWork W2976825301 @default.
- W2999694147 hasRelatedWork W3000005566 @default.
- W2999694147 hasRelatedWork W3151181350 @default.
- W2999694147 hasRelatedWork W943998695 @default.
- W2999694147 isParatext "false" @default.
- W2999694147 isRetracted "false" @default.
- W2999694147 magId "2999694147" @default.
- W2999694147 workType "article" @default.